Skip to content
10-Q

Quarterly Report

SELLAS Life Sciences Group, Inc. SLS

0001390478-26-000008

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 186.03M sh
Shares Diluted Q1 2026 · Mar 31, 2026 172.48M sh
Shares Diluted Q1 2026 · Mar 31, 2025 87.76M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$8.85M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$9.07M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $107.1M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $71.79M
Stockholders Equity Q1 2026 · Mar 31, 2026 $107.41M
Stockholders Equity Q1 2026 · Dec 31, 2025 $70.87M
Stockholders Equity Q1 2026 · Mar 31, 2025 $27.76M
Stockholders Equity Q1 2026 · Dec 31, 2024 $9.47M
Current Liabilities Q1 2026 · Mar 31, 2026 $6.46M
Current Liabilities Q1 2026 · Dec 31, 2025 $7.02M
Total Liabilities Q1 2026 · Mar 31, 2026 $6.77M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.47M
Current Assets Q1 2026 · Mar 31, 2026 $111.17M
Current Assets Q1 2026 · Dec 31, 2025 $75.21M
Total Assets Q1 2026 · Mar 31, 2026 $114.18M
Total Assets Q1 2026 · Dec 31, 2025 $78.35M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.05
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.07
Eps Basic Q1 2026 · Mar 31, 2026 −$0.05
Eps Basic Q1 2026 · Mar 31, 2025 −$0.07
Net Income Q1 2026 · Mar 31, 2026 −$8.41M
Net Income Q1 2026 · Mar 31, 2025 −$5.81M
Operating Income Q1 2026 · Mar 31, 2026 −$9.25M
Operating Income Q1 2026 · Mar 31, 2025 −$6.06M